Astrazeneca Plc $AZN Shares Bought by Penobscot Investment Management Company Inc.

Penobscot Investment Management Company Inc. boosted its position in shares of Astrazeneca Plc (NYSE:AZN) by 17.2% in the 4th quarter, Holdings Channel.com reports. The institutional investor owned 83,539 shares of the company’s stock after buying an additional 12,255 shares during the period. Penobscot Investment Management Company Inc.’s holdings in Astrazeneca were worth $7,680,000 at the end of the most recent reporting period.

Other large investors also recently bought and sold shares of the company. Triumph Capital Management purchased a new stake in Astrazeneca during the 3rd quarter worth approximately $25,000. Bangor Savings Bank increased its stake in Astrazeneca by 102.7% during the 4th quarter. Bangor Savings Bank now owns 304 shares of the company’s stock worth $28,000 after buying an additional 154 shares in the last quarter. Eagle Bay Advisors LLC purchased a new stake in Astrazeneca during the 4th quarter worth approximately $30,000. Rakuten Investment Management Inc. purchased a new stake in Astrazeneca during the 3rd quarter worth approximately $31,000. Finally, YANKCOM Partnership purchased a new stake in Astrazeneca during the 4th quarter worth approximately $31,000. 20.35% of the stock is currently owned by hedge funds and other institutional investors.

Astrazeneca Stock Performance

AZN stock opened at $195.94 on Wednesday. The company has a quick ratio of 0.72, a current ratio of 0.94 and a debt-to-equity ratio of 0.51. The company has a market capitalization of $303.88 billion, a PE ratio of 33.75, a P/E/G ratio of 1.51 and a beta of 0.35. Astrazeneca Plc has a 1 year low of $132.32 and a 1 year high of $212.71.

Astrazeneca Dividend Announcement

The business also recently declared a dividend, which was paid on Monday, March 23rd. Stockholders of record on Friday, February 20th were given a $1.595 dividend. The ex-dividend date was Friday, February 20th. This represents a dividend yield of 156.0%. Astrazeneca’s dividend payout ratio is 74.83%.

Astrazeneca News Summary

Here are the key news stories impacting Astrazeneca this week:

• Positive Sentiment: Ultomiris met the primary endpoint in a Phase III trial for IgA nephropathy (statistically significant reduction in proteinuria), supporting prospects for accelerated approvals and label expansion in a rare kidney disease. AstraZeneca’s Ultomiris reduces urine protein in late-stage trial of rare kidney disease
• Positive Sentiment: Tozorakimab delivered a third Phase III success (MIRANDA) with a sharp reduction in moderate‑to‑severe COPD flare‑ups; Citi sees blockbuster potential (~$5bn peak sales) — a material long‑term revenue catalyst if launches and uptake follow. AstraZeneca’s tozorakimab delivers sharp reduction in COPD flare‑ups
• Neutral Sentiment: Broker consensus remains constructive (average “Moderate Buy”), which supports near‑term analyst backing but may already be reflected in the share price. Astrazeneca Plc (NYSE:AZN) Given Average Rating of “Moderate Buy” by Brokerages
• Negative Sentiment: AstraZeneca’s CEO warned Germany risks missing out on new drugs if it tightens pharmaceutical spending — a signal of potential pricing/reimbursement headwinds in a major European market that could slow adoption and revenue ramp for new launches. Germany risks missing out on new drugs, AstraZeneca CEO tells paper

Wall Street Analyst Weigh In

AZN has been the subject of several research reports. TD Cowen reiterated a “buy” rating on shares of Astrazeneca in a research note on Wednesday, March 18th. Weiss Ratings initiated coverage on Astrazeneca in a research note on Wednesday, March 11th. They set a “buy (b)” rating for the company. Citigroup initiated coverage on Astrazeneca in a research note on Tuesday, January 27th. They set a “buy” rating for the company. Wall Street Zen lowered Astrazeneca from a “buy” rating to a “hold” rating in a research note on Saturday, April 4th. Finally, Morgan Stanley reiterated an “overweight” rating on shares of Astrazeneca in a research note on Wednesday, April 8th. Eight analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Astrazeneca has a consensus rating of “Moderate Buy” and an average price target of $102.67.

Astrazeneca Company Profile

AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.

The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.